Clinical Trial Update: Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study of oral ixazomib in adults with relapsed or refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Multiple Myeloma

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Relapsed and Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2019-08-07